By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – SQI Diagnostics today announced it has amended its deal to buy Scienion in order to push back the date by which the deal can be terminated.

The termination date is now Oct. 5, changed from the original date of Sept. 30. No reason was given for the change. SQI also has agreed to issue an additional 173,797 common shares of its stock to Scienion in consideration of the extension, the Toronto-based company said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.

A National Science Foundation-funded project aims to give researchers access to a network many times faster than the Internet.

Bioethicists weigh the idea of charging patients to take part in clinical research, coming down against the approach.

Cornell's Christopher Mason and his colleagues correct their New York City microbiome study to emphasize "the difference between matching fragments of DNA from a species and a pathogen."